California and five other states on June 22 joined the Federal Trade Commission's antitrust lawsuit to block Thousand Oaks-based biotech giant Amgen from buying another life sciences company, Horizon Therapeutics, for nearly $28 billion. Horizon, based in Illinois and Ireland, has a monopoly on Tepezza, a medicine that treats thyroid eye disease, and Krystexxa, a…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
